Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)
Active, not recruitingOBSERVATIONAL
Enrollment
1,000
Participants
Timeline
Start Date
April 20, 2020
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
Conditions
Adrenocortical Carcinoma
Trial Locations (1)
20892
National Cancer Institute (NCI), Bethesda
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT04358107 - Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC) | Biotech Hunter | Biotech Hunter